Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen

SEATTLE, July 30, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
July 27, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Registration Is Now Open for Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event on July 30, 2020

SEATTLE, July 27, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company with a current focus on breast cancer and COVID-19, announces that...
July 16, 2020 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa’s Second COVID-19 Therapeutic Development Program

SEATTLE, July 16, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
July 15, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
July 08, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls

SEATTLE, July 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
June 11, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201

SEATTLE, June 11, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
May 28, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study

SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
May 20, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

SEATTLE, May 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
May 13, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs

SEATTLE, May 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
May 07, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment

SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...